SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc.
(Nasdaq: INBX), a biotechnology company with four clinical programs
in development and an emerging pre-clinical pipeline, announced
today that the Company will be presenting at the Connective Tissue
Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place
November 10-13, 2021.
CTOS Virtual Presentation Details:
Title: Safety and Efficacy of the Tetravalent Death Receptor 5
Agonist INBRX-109 in Patients with Conventional Chondrosarcoma:
Update from the Phase 1 Expansion Cohort
Lead Author: Vivek Subbiah, MD
Abstract: 1082377, (P 018)
Oral Presentation on Thursday, November
11th at 1:29 p.m. –
1:36 p.m. Eastern Time
Title: Tetravalent Death Receptor 5 Agonist INBRX-109 in Ewing
Sarcoma: Planned Phase 1 Cohort Expansion Guided by Preclinical
Data
Lead Author: Emily Rowell, PhD
Abstract: 1818985, (P 090)
Poster Presentation on Thursday, November
11th at 2:30 p.m. –
3:15 p.m. Eastern Time
Additionally, the Company will be presenting at the following
upcoming virtual investor conferences:
- The Credit Suisse 30th Annual Healthcare Conference;
Tuesday, November 9th at 3:30 p.m. Eastern Time;
- The Stifel 2021 Healthcare Conference; Tuesday, November 16th at 10:00 a.m. Eastern Time;
- The Jefferies London Healthcare Conference; November 16th–19th;
Pre-recorded for conference attendees and available post-conference
on Inhibrx's website;
- The Evercore ISI 4th Annual HealthCONx Conference;
Wednesday, December 1st at
3:30 p.m. Eastern Time; and
- The JMP Securities Hematology and Oncology Summit; Tuesday, December 7th at 2:00 p.m. Eastern Time.
The scientific posters and presentation will be accessible
through a link on the investors section of Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations. The
investor conference presentations will be webcast live and will
also be accessible through the same link. The webcasts will be
available for at least 60 days following the event.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with bluebird
bio, Bristol-Myers Squibb and Chiesi. For more information, please
visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-and-investor-conferences-301413398.html
SOURCE Inhibrx, Inc.